Persistent Severe Acute Respiratory Syndrome coronavirus-2 (SARS-CoV-2) infection is observed among patients with haematological malignancy, conferring an increased mortality risk. Persistent SARS-CoV-2 RNA detection from clinical samples may represent redundant fragmented RNA, replication-competent virus, or reinfection.

Given the role of the host immune response in viral clearance and COVID-19 immunopathogenesis, distinguishing these scenarios is important for therapeutic decision-making (antiviral versus immunomodulatory) as well as preventing onward hospital transmission. Optimal timing of subsequent chemotherapy cycles is challenging, since relapse of COVID-19 can occur in individuals with impaired humoral responses.

We present the investigation of relapsing SARS-CoV-2 pneumonitis, with virological persistence evidenced by SARS-CoV-2 cell culture and sequencing, in the context of cellular and humoral immunodeficiency secondary to underlying lymphoma and chemo-immunotherapy. The potential clinical benefit of cell culture is discussed.

**Investigation**

The patient was investigated for persisting SARS-CoV-2 infection/reinfection following relapsing symptomatic pneumonitis associated with positive RNA-polymerase chain reaction (PCR) testing after second-round chemotherapy. Investigation was conducted as per current Public Health England guidelines, including infection specialist advice, in-house whole-genome sequencing (WGS) and immunological testing using both B-cell and T-cell assays (Data S1). Additionally, in-house viral cell culture was conducted to assess for replication-competent virus (Data S1).

**Case**

A 65-year-old lady who underwent a renal transplant in 1995 for focal segmental glomerulonephritis, followed by long-term immunosuppression with tacrolimus, subsequently developed low-level lymphocytosis in 2017. Immunophenotyping confirmed a B-cell non-Hodgkin lymphoma (NHL), histologically most likely to be diffuse large B-cell lymphoma, associated with an IgM paraprotein of 6 g/l for which she was managed expectantly.

In November 2020, she presented acutely with abdominal pain. Computed tomography (CT) imaging demonstrated a bulky retroperitoneal soft tissue mass at the porta hepatis, associated with 4 kg of weight loss. A bone marrow aspirate demonstrated infiltration with a CD19-positive, CD5-negative B-cell NHL. Gastroscopy showed abnormal appearance of gastric folds and gastric biopsy confirmed CD5 stage IVB high-grade B-cell NHL.

On 7 December 2020, four days post first-cycle R-CHOP (rituximab/cyclophosphamide/doxorubicin/vincristine and prednisolone) chemotherapy, our patient tested PCR-positive for SARS-CoV-2 infection associated with cough, fever, and shortness of breath without oxygen requirement. Ongoing symptomatic and PCR-positive SARS-CoV-2 infection with cough/dyspnoea (day 21) delayed a second cycle. Due to the lack of oxygen requirement at this time, neither remdesivir nor dexamethasone were administered. On day 52, once symptoms had fully resolved and a SARS-CoV-2 PCR was negative, she received a delayed second cycle of chemotherapy. Neutropenia (0.0 × 10⁹/l) and fever (38°C) subsequently developed (day 58; Fig 1A,B). Lymphocyte count was 0.0 × 10⁹/l, remaining <1.0 × 10⁹/l for 38 days post-chemotherapy. Further SARS-CoV-2 PCR tests were positive on days 58/59/63/67 (same B.1.177.5 lineage, Fig 2). Six doses of granulocyte colony-stimulating factor (G-CSF) were administered on days 58–60, 62–64 (neutrophil nadir 0.0, peak 6.6 × 10⁹/l). Tacrolimus levels remained within range. New bilateral pulmonary infiltrates on chest imaging (Fig 1), a C-reactive protein (CRP) level of 326 mg/l and a rising neutrophil count followed (day 66), alongside new oxygen requirements. Investigation for possible co-infection included urinary, sputum, serial blood cultures as well as carrying out PCR on ethylenediamine tetra-acetic acid (EDTA) blood for cytomegalovirus (CMV) and adenovirus. Atypical urinary antigens and a syndromic respiratory PCR panel (Biofire Respiratory 2-1, BioFire Diagnostics [bioMérieux], Salt Lake City, UT, USA) targeting 22 virus and bacteria targets were also conducted. All results were negative. Increased prednisolone (40 mg daily, tapering 10 mg daily every 5 days) and remdesivir (200 mg stat, 100 mg daily for 5 days) were commenced (day 67): fever, dyspnoea and oxygen requirement resolved, and CRP declined to 22 mg/l (Fig 1B).

PCR tests remained positive on days 76 [decreased cycle threshold number (Ct) value], 83, 86 and 91, becoming negative from day 134 onwards (Fig 1A). Viral cell culture performed on day 64 and 86 (before and after remdesivir, with...
both swabs also PCR-positive) demonstrated replication-competent virus [approximately 400-fold increase of detectable RNA over inoculum (Fig 1)]. WGS of viral RNA showed ongoing infection with the same B.1.177.5 lineage throughout (Fig 2), acquiring three single nucleotide polymorphisms (SNPs) between days 1 and 63 and a further five SNPs between days 64 and 86 (after remdesivir).

SARS-CoV-2-specific anti-nucleocapsid and anti-spike (anti-S) antibodies were negative, whereas enzyme-linked immunosorbent spot (ELISpot) readout was positive (>160 spots across the S1/S2 panels) indicating robust T-cell responses to a panel of SARS-CoV-2-specific peptide pools.

**Discussion**

Determining SARS-CoV-2 viability in patients with haematological malignancy has implications for treatment-based decision-making. For example, B-cell depletion with rituximab should ideally be held during viable SARS-CoV-2 infection, to avoid hindering antibody responses. In this case, viral cell culture results alongside WGS supported reactivation of symptomatic infection and led to the decision to treat with a full course of high-dose steroids and remdesivir.

Moreover, administration of G-CSF therapy for supportive management of chemotherapy-induced neutropenia was highlighted as a possible risk for further symptomatic (fever, breathlessness) disease in the presence of infection with replication-competent SARS-CoV-2 virus. Recognition of replication-competent virus prior to administration of G-CSF may therefore allow improved patient understanding of risk and advanced planning should pneumonitis develop.

In addition to stimulating neutrophil proliferation and maturation, G-CSF reconstitutes immune mediators including the pro-inflammatory cytokines interleukin-1, tumour necrosis factor alpha (TNF-α), and interferon-γ (IFN-γ). These cytokines play a role in both innate and adaptive immune responses and are critical for the initiation and amplification of the immune response to SARS-CoV-2 infection.
factor (TNF)-α and interleukin-6,6 which play a role in a mal-adaptive inflammatory response to SARS-CoV-2 infection.10

Furthermore, autopsy studies reveal aggregated neutrophils and neutrophil extracellular traps in lung tissue,11 induced by a mechanism that appears dependent on active SARS-CoV-2 viral replication.10 We therefore postulate that rising neutrophils following G-CSF therapy during active SARS-CoV-2 infection may have led to relapsing pneumonitis in this manner, clinically resembling paradoxical immune reconstitution inflammatory syndromes (IRIS; Fig 1B), occasionally seen with treatment initiation of HIV or tuberculosis,12,13 with one such case reported.14 As with IRIS, treatment with steroids may have contributed to resolution of CRP and oxygen requirement (Fig 1) although timing of G-CSF alongside steroids is a confounding factor that makes further interpretation in this case difficult.

A further consideration is the potential for ongoing infectivity despite remdesivir treatment and symptom resolution. Clinical and virological resolution, based on Ct values, following remdesivir treatment in B-cell deficiency have been reported.7 Contrary to these findings we note a cell culture demonstrated persisting replication-competent virus. Viral cell cultures appear to be of additional value in understanding infection dynamics: our findings caution against the use of Ct values alone in inferring virological resolution. Ongoing culture/PCR positivity was managed by negative-pressure-room isolation and adherence to infection prevention and control procedures until discharge from hospital. Phylogenetic analysis of WGS of SARS-CoV-2 isolated from hospitalised patients and staff over the same period did not demonstrate temporally associated onward transmission.

While there was no acceleration in the rate of SNPs from an estimated baseline (1–2/month) during persistent infection, there was a relative increase (five SNPs) following remdesivir treatment, suggesting an increased rate of SARS-CoV-2 mutation,15 although no significant changes were noted in the remdesivir-binding portion (Fig 2). This is in keeping with observation of viral evolution during treatment of chronic SARS-CoV-2 reported elsewhere.16

Failure to detect SARS-CoV-2-specific antibodies is unsurprising. A T-cell response was noted, however, despite treatment throughout with low-dose tacrolimus. The detection of adequate SARS-CoV-2-specific T-cell responses adds to the growing recognition that T-cell-mediated immunity can lead to eventual viral resolution, even in the absence of antibodies,17 albeit at an extended pace.

Our report is limited by discussion of a single case. Additional examples may help to define the potential role for viral cell culture further. One such example may be in supporting infection prevention control decisions. The potential for false negative SARS-CoV-2 PCR swabs is recognised and it may therefore be prudent to acquire serial negative swabs to increase confidence prior to chemotherapy based on our findings.

Conclusions

Immunomodulation may have contributed to replication of residual competent virus in this case, while immune stimulation with G-CSF, and subsequent neutrophil reconstitution, may have contributed to relapsing, symptomatic pneumonitis. Viral cell culture alongside steroids is of additional value in understanding infection dynamics: our findings caution against the use of Ct values alone in inferring virological resolution.

Immunodeficient patients with persistent SARS-CoV-2 infection several months after initial infection may harbour potential for onward transmission of replication-competent virus. The risk of recurrent pneumonitis should be considered when planning immunomodulatory treatment.

Acknowledgements

The authors thank South West London Pathology for carrying out molecular diagnostics and assessment of haematology
and biochemistry samples as part of routine clinical care. WGS reporting was generated using CIVET 2.0, primarily created by Aine O'Toole and Verity Hill, utilising code provided by Rambaut Lab members. Background genomic data were made available through the UK-COG consortium (www.cogconsortium.uk). Some further background data in the phylogenies were also made available by GISAID (www.gisaid.org). We thank everyone involved in the global sequencing effort for making their data readily available. The views expressed in this publication are those of the authors and not necessarily those of the NHS, the Ministry of Defence, or the UK Department of Health.

Ethics

SARS-CoV-2 PCR testing was carried out as part of routine clinical activity. WGS and immunological testing was carried out while investigating for possible SARS-CoV-2 reinfection following consultation with infectious diseases specialist advice and in line with current Public Health England guidance for investigation of possible cases of SARS-CoV-2 reinfection. Viral cell culture was completed in order to investigate possible ongoing infectious potential and guide decision-making on in-patient management (in isolation on infectious diseases ward versus under the direct care of the haematology team on the haematology unit) and was therefore, as per National Research Ethics Service guidance, not considered research activity. Informed written consent for case publication was provided by the patient. The case has been reported in line with the case report (CARE) guidelines and in compliance with the Declaration of Helsinki principles.

Funding

WGS was partially funded by the COVID-19 Genomics-UK (COG-UK) Consortium. COG-UK is supported by funding from the Medical Research Council (MRC) part of UK Research & Innovation (UKRI), the National Institute of Health Research (NIHR) and Genome Research Limited, operating as the Wellcome Sanger Institute. The corresponding author had full access to all of the data and the final responsibility to submit for publication.

Author contributions

SJCP, RW, JY, CP and TB designed the study. CP and MH carried out molecular diagnostics. JT and NK located nasopharyngeal swabs, performed nucleic extraction and managed results. KL and IM performed WGS. AW provided analysis of virus lineages. EG performed viral cell culture. SJCP, RW, LH, NK and MA analysed the data. SJCP and RW drafted the initial manuscript with all authors contributing significantly to revising this for submission. All authors reviewed the results and data analysis and contributed comments. All authors agreed on the final version for submission to the journal.

Conflicts of interest

TB has received research funding and speaker fees from Gilead sciences and Pfizer. SJCP has received a research grant from the Scientific Exploration Society supported by the Viscount Gough. PK has received support to use the T-SPOT Discovery SARS-CoV-2 from Oxford Immunotec. All other authors have no conflicts of interest to declare.

Data availability statement

The data analysed during the current study and further details on the assays are available from the corresponding author (SJCP; scott.pallett@nhs.net) on reasonable request, as long as this meets local ethical and research governance criteria.

Scott J. C. Pallett1,2
Rachel Wake1,3
Jonathan Youngs1
Cassie Pope1,3
Ngee Keong Tan4
Joshua Taylor4
Lois Hawkins1
Adam A. Witney3
Kenneth G. Laing3
Irene M. Monahan3
Melek Akay5
Alison Cox6
Elisabetta Groppelli3
Peter Kelleher6
Paul Miller5
Tihana Bicanic1,3

1Infection Care Group, St George’s University Hospitals NHS Foundation Trust, London, 2Centre of Defence Pathology, Royal Centre for Defence Medicine, Edgbaston, Birmingham, 3Institute for Infection and Immunity, St George’s University of London, Cranmer Terrace, 4South West London Pathology, Jenner Wing, St. George’s Hospital, 5Department of Haematology, St George’s University Hospitals NHS Foundation Trust and 6Centre for Immunology and Vaccinology, Department of Medicine, Imperial College London, London, UK.
E-mail: scott.pallett@nhs.net

Keywords: COVID-19, SARS-CoV-2, recurrence, lymphoma, immune reconstitution

Supporting Information

Additional supporting information may be found online in the Supporting Information section at the end of the article.

Data S1. Detailed methods are described for (i) immunological testing, (ii) SARS-CoV-2 RNA PCR testing, (iii) in-
References

1. Shah V, Ko Ko T, Zuckerman M, Vidler I, Sharif S, Mehra V, et al. Poor outcome and prolonged persistence of SARS-CoV-2 RNA in COVID-19 patients with haematological malignancies: King’s College Hospital experience. Br J Haematol. 2020;190:e279–e282. https://doi.org/10.1111/bjh.16935

2. Bhogal T, Khan UT, Lee R, Stockdale A, Hesford C, Potti-Dhananjaya V, et al. Haematological malignancy and nosocomial transmission are associated with an increased risk of death from COVID-19: results of a multicenter UK cohort. Leuk Lymphoma. 2021;62(7):1682–1691. https://doi.org/10.1080/10428194.2021.1876865

3. Piralla A, Ricchi M, Cusi MG, Prati P, Vicari N, Scarsi G, et al. Residual SARS-CoV-2 RNA in nasal swabs of convalescent COVID-19 patients: is prolonged quarantine always justified? Int J Inf Dis. 2021;102:299–302. https://doi.org/10.1016/j.ijid.2020.10.072

4. Graham MS, Sudre CH, May A, Antonelli M, Murray B, Varsavsky T, et al. Changes in symptomatology, reinfection, and transmissibility associated with the SARS-CoV-2 variant B.1.1.7: an ecological study. Lancet Public Health. 2021;6(5):e335–e345. https://doi.org/10.1016/S2468-2667(21)00055-4

5. Zirui Tay M, Meng Poh C, Renia L, Macary PA, Ng LFP. The trinity of COVID-19: immunity, inflammation and intervention. Nat Rev Immunol. 2020;20(6):363–74. https://doi.org/10.1038/s41577-020-0311-8

6. Wang X, He Z, Zhao X. Immunoregulatory therapy strategies that target cytokine storms in patients with COVID-19 (Review). Exp Ther Med. 2021;21(4):319. https://doi.org/10.3892/etm.2021.9750

7. Buckland MS, Galloway JB, Flughartagh CN, Meredith L, Provine NM, Bloor S, et al. Treatment of COVID-19 with remdesivir in the absence of humoral immunity: a case report. Nat Commun. 2020;11:6358.

8. Public Health England. Guidance: Investigation and management of suspected SARS-CoV-2 reinfections: a guide for clinicians and infection specialists. Available from: https://www.gov.uk/government/publications/covid-19-investigation-and-management-of-suspected-sars-cov-2-reinfections/investigation-and-management-of-suspected-sars-cov-2-reinfections-a-guide-for-clinicians-and-infection-specialists (Accessed 15 May 21).

9. Prendercki M, Clarke C, Brown J, Cox A, Gleeson S, Guckian M, et al. Effect of previous SARS-CoV-2 infection on humoral and T-cell responses to single-dose BNT162b2 vaccine. Lancet. 2021;397(10280):1178–81. https://doi.org/10.1016/S0140-6736(21)00502-X

10. Prostasio Veras F, Cornejo Pontelli M, Meireles Silva C, Toller-Kawahisa JE, de Lima M, Carvalho Nascimento D, et al. SARS-CoV-2–triggered neutrophil extracellular traps mediate COVID-19 pathology. J Exp Med. 2020;217(12):e20201129. https://doi.org/10.1084/jem.20201129

11. Schurink B, Roos E, Radonic T, Barbe E, Bouman CSC, de Boer HH, et al. Viral presence and immunopathology in patients with lethal COVID-19: a prospective autopsy cohort study. Lancet Microbe. 2020;1(7): E290–9. https://doi.org/10.1016/S2666-5247(20)30144-0

12. Seddiki N, French M. COVID-19 and HIV-associated immune reconstitution inflammatory syndrome: emergence of pathogen-specific immune responses adding fuel to the fire. Front Immunol. 2021;12:649567. https://doi.org/10.3389/fimmu.2021.649567

13. Malek AE. Time to revisit the use of G-CSF after allogeneic hematopoietic cell transplantation in COVID-19 era? Br J Cancer. 2021;124:1183. https://doi.org/10.1038/s41416-020-01195-8

14. Mertens J, Laghrib Y, Kenyon C. A case of steroid-responsive, COVID-19 immune reconstitution inflammatory syndrome following the use of granulocyte colony-stimulating factor. Open Forum Infect Dis. 2020;7(8): oofa326. https://doi.org/10.1093/ofid/ofaa326

15. Barclay W, Evans C, Darby A, Rambaut A, Pybus O, Robertson D, et al. NERVTAG report: Is there evidence for genetic change in SARS-CoV-2 and if so, do mutations affect virus phenotype? 2020. Available from: https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/928724/S0790_NERVTAG_-_Is_there_evidence_for_genetic_change_in_SARS-CoV-2.pdf (Last accessed 05 May 21).

16. Boshier FAT, Pang I, Penner J, Hughes J, Parker M, Shepherd J, et al. Remdesivir induced viral RNA and subgenomic RNA suppression, and evolution of viral variants in SARS-CoV-2 infected patients. medRxiv. 2020. https://doi.org/10.1101/2020.11.18.20230599 (Accessed 14th May 21).

17. Clarke CL, Prendercki M, Dhutia A, Gan J, Edwards C, Prout V, et al. Longevity of SARS-CoV-2 immune responses in hemodialysis patients and protection against reinfection. Kidney Int. 2021; 99(6):1470–1477. https://doi.org/10.1016/j.kint.2021.03.009